GYGang Yao

Gang Yao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gang Yao has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Feng-Yan Xie

    2nd Affiliated Hospital of Nanjing Medical University

    1 shared publication
  • Fengyan Xie

    Department of Nephrology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, PR China

    1 shared publication
  • Haizhen Zhong

    Department of Nephrology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, PR China

    1 shared publication
  • Hui-Mei Chen

    Nanjing University

    1 shared publication
  • Huimei Chen

    Jiangsu Key Laboratory of Molecular Medicine, School of Medicine, Nanjing University

    1 shared publication
  • Huimei Chen

    National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

    1 shared publication

Latest Publications

  • Salvianolic acid B reverses the epithelial-to-mesenchymal transition of HK-2 cells that is induced by transforming growth factor-β

    by Rong-Hua Pan, Feng-Yan Xie, Hui-Mei Chen, Li-Zhi Xu, Xiao-Chun Wu, Ling-Ling Xu, Gang Yao

    Salvianolic acid B (Sal B) is the most abundant bioactive molecule from Radix Salviae Miltiorrhizae, and has recently been used for treating renal fibrosis in traditional Chinese medicine. Here we investigated the ability reversal of Sal B to reverse the transdifferentiation of human kidney proximal tubular epithelial cells that was induced by transforming growth factor-beta 1 (TGF-β1). The effects of Sal B on HK-2 cell morphology were observed by phase contrast microscopy, while alpha smooth muscle actin and E-cadherin were studied by immunocytochemistry and real-time reverse transcription polymerase chain reaction, respectively. Exposure of HK-2 cells to TGF-β1 for 72 h induced a complete conversion of the epithelial cells to myofibroblasts. When HK-2 cells were co-incubated with Sal B and TGF-β1 for a further 72 h, the morphology of myofibroblasts returned to that of proximal tubular epithelial cells, whereas the myofibroblast phenotype was maintained after exposure of cells to TGF-β1 for 144 h. Sal B reduced alpha smooth muscle actin levels and increased E-cadherin levels compared with their epithelial-to-mesenchymal transition controls. The reversal effect of Sal B was dose-dependent. That Sal B reverses the epithelial-to-mesenchymal transition in vitro suggests that it could possibly facilitate the repair of tubular epithelial structures and the regression of renal fibrosis in injured kidneys.


  • Preventive Effects of Salvianolic Acid B on Transforming Growth Factor-β1-Induced Epithelial-to-Mesenchymal Transition of Human Kidney Cells

    by Gang Yao, Lizhi Xu, Xiaochun Wu, Lingling Xu, Junwei Yang, Huimei Chen

    Epithelial-mesenchymal transition (EMT) is an important mechanism in kidney fibrosis. While Salvianolic acid-B (Sal B) has been well appreciated to show a protective effect of tissue fibrosis, the objective of this study was to investigate the influence of Sal B on the transdifferentiation of renal tubular epithelial cells. Human kidney proximal tubular cell line (HK-2) was used as the proximal tubular cell model and EMT was induced with 5 ng/ml of human transforming growth factor (TGF)-beta1. The effects of the Sal B on cell morphology were observed by phase contrast microscopy, and the possible mechanisms were studied by immunocytochemistry and real-time reverse transcription-polymerase chain reaction. Our results revealed that Sal B could inhibit TGF-beta1-induced myofibroblast phenotype and restored the epithelial morphology in a dose-dependent manner. It was partially through modulating alpha-smooth muscle actin (SMA) increase and E-cadherin reduction. These observations strongly suggest that Sal B is a potent inhibitor of TGF-beta1-induced EMT and might be a promising agent for treating tubulointerstitial fibrosis.